Member Info for Hurst10

Nice print after hours

Two hottest IPO’s this autumn:

Avacta and Birkenstock, major houses will be fighting to get the ticket for the deal.

With expected news flow ahead, no surprise early kick off in NY, watch BB on the bid and quietly picking up what they can get ,before a crowded book have to make attractive bids to get stock.No sellers above 100! A lively day ahead.

Would expect follow up buying this afternoon, the so called “shorts “ are getting rather rattled and we will see more “ I surrender “ trades later on, with size buyers picking up everything available at these levels, before we will have 40% upside and we will talk about this week’s trades as the easiest way of making substantial returns, the trick is : Never sell, as you will end up paying much more getting back in again.

Indeed, watch the stock exchange’s prints

Indeed, most likely heard in a coffee shop” what would happen if we make a bit of noise and buy size.”

Any way you could resend the link.

Have problems opening it.

The majors are buying

Biogen and its new CEO are finally wading into 2023’s M&A wave with a $7.3 billion deal for Reata Pharmaceuticals, which just secured FDA approval for a rare genetic disease.

Dare I use the word?

“ size buyers are back “

It seems we got buyers back in town

If one were to apply a proper IPO valuation of Affyxell, then Avacta’s holding in the company at no cost, would be close to the current m/c of Avacta.

We are all aware of the amazing progress we have seen with AVA6000 and AVA3996 and when the company does makes a Cohort update and indeed the FDA with fast tracking ref AVA6000 and the the very real possibility of a substantial license deal and fast tracking an IPO of the Therapeutic division. It is worth remembering when the company made the recent acquisition in the Diagnostic division of Coris, at the AGM, Avacta spoke of continuing to benefit from cross synergies across the division, which one would assume would include the cost savings benefits of halting the redevelopment of its own AffiDX SARS-CoV-2 antigen lateral flow test.

40/ just printed on the buy side,cannot blame them at this price, in front of what could be a lively week!

Cell therapy startup Turnstone adds to biotech IPO flurry with $80M raise

The offering is the fourth for the sector this month, the first time that’s happened in nearly a year and a half, according to BioPharma Dive data.

Thanks

English version on their site?

Interesting to note that on page 15,

Avacta Diagnostic “ Review and Growth “, beneath the Growth title, there is now a mention of

“ potential future spin-out opportunity “!

Would indicate a separate US listing of the therapeutic division, with a pipeline of selective and focused out-licensing.

Roche have their earnings Webinar at 13.00 hrs

Should be useful and interesting comments on the sector.

Interesting article on CDMO and I thought relevant to Affyxell and GenScript Pro Bio.

From article:

“As the CGT industry matures, CDMO outsourcing is expected to increase dramatically, playing an even more critical role in advanced therapy production. In addition, the IP landscape and quality control standards will become clearer as regulations are better defined, resulting in an even higher degree of expertise and level of capabilities offered in the outsourcing service provider marketplace. “

https://www.biopharmadive.com/spons/cell-and-gene-therapy-is-coming-of-age/688569/

Interesting opening tomorrow